SETD2 mediates immunotherapy and radiotherapy efficacy via regulating DNA damage responses and genomic stability in lung adenocarcinoma
返回论文页
Short communication|更新时间:2023-05-16
|
SETD2 mediates immunotherapy and radiotherapy efficacy via regulating DNA damage responses and genomic stability in lung adenocarcinoma
SETD2 mediates immunotherapy and radiotherapy efficacy via regulating DNA damage responses and genomic stability in lung adenocarcinoma
Genes & Diseases2023年10卷第2期
作者机构:
1. Tumor Precision Diagnosis and Treatment Technology and Translational Medicine, Hubei Engineering Research Center, Zhongnan Hospital of Wuhan University,Hubei,Wuhan,China,430071
2. Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University,Hubei,Wuhan,China,430071
3. Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University,Hubei,Wuhan,China,430071
4. Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University,Hubei,Wuhan,China,430071
5. Department of Biological Repositories, Zhongnan Hospital of Wuhan University,Hubei,Wuhan,China,430071
SETD2 mediates immunotherapy and radiotherapy efficacy via regulating DNA damage responses and genomic stability in lung adenocarcinoma[J]. Genes & Diseases, 2023,10(2).
Zihang Zeng, Yanping Gao, Jiali Li, et al. SETD2 mediates immunotherapy and radiotherapy efficacy via regulating DNA damage responses and genomic stability in lung adenocarcinoma[J]. Genes & Diseases, 2023,10(2).
SETD2 mediates immunotherapy and radiotherapy efficacy via regulating DNA damage responses and genomic stability in lung adenocarcinoma[J]. Genes & Diseases, 2023,10(2). DOI: 10.1016/j.gendis.2022.02.016.
Zihang Zeng, Yanping Gao, Jiali Li, et al. SETD2 mediates immunotherapy and radiotherapy efficacy via regulating DNA damage responses and genomic stability in lung adenocarcinoma[J]. Genes & Diseases, 2023,10(2). DOI: 10.1016/j.gendis.2022.02.016.
SETD2 mediates immunotherapy and radiotherapy efficacy via regulating DNA damage responses and genomic stability in lung adenocarcinoma